Abstract: A method for manufacturing an antiviral pharmaceutical composition for the prophylaxis or treatment of a rhinovirus infection that includes the utilization of iota-, kappa- or lambda-carrageenan or mixtures thereof.

Abstract: The present invention provides the use of cellulose sulfate or chitosan for the manufacture of an anti-inflammatory pharmaceutical or cosmetic composition for the treatment of inflammation.

Abstract: Nucleotide sequences and fragments which code for a human endogenous retrovirus which is infectious. “Fragments” according to the present invention relate also to specific fragments of the sequences inserted into the vector pCR4-Topo and deposited as MERV-env, MERV-gag, MERV-prt and MERV-pol as mentioned above. Additionally, methods of using such sequences, polypeptides encoded by such sequences, antibodies directs against such sequences, and methods and compositions relating to the same are all contemplated.

Abstract: Described is a polynucleotide molecule being a fragment of a polynucleotide sequence of an infectious human endogenous retrovirus, said polynucleotide molecule comprising a sequence selected from the group consisting of (a) a sequence with at least 98%, preferably 99%, still preferred 99.5%, identity to a sequence according to SEQ ID No 1, (b) a sequence which hybridises under stringent conditions with a nucleotide sequence according to said SEQ ID No 1, (c) a sequence which differs from said sequences (a) or (b) due to degeneration of the genetic code and (d) a sequence comprising sequences inserted into vectors pCR4-Topo and deposited as “MERV-env”, “MERV-gag”, “MERV-prt” and “MERV-pol” at the DSMZ on 26 Sep. 2001 or fragments thereof.

Abstract: The invention relates to a method and a device for generating Alfvén waves, in which ionizable material is provided that penetrates a magnetic field. In order to create such a method or a device in which material can be conveyed based on the Alfvén waves, the magnetic field consists of a primary magnetic field that is periodically deformed by at least one oscillating secondary magnetic field that is polarized in the opposite direction from the primary field such that Alfvén waves are created in the ionizable material located in said magnetic field. The Alfvén waves propagate at a speed that depends on the density of the material penetrating the magnetic field and the field intensity of the magnetic field. The field intensity of the magnetic field is greater than the kinetic energy of the material located in the magnetic field such that material is conveyed by means of the Alfvén waves.

Abstract: The present invention provides the use of carrageenan or mixtures thereof for the manufacture of an antiviral pharmaceutical composition for the treatment of rhinovirus infections.

Abstract: Nucleotide sequences and fragments which code for a human endogenous retrovirus which is infectious. “Fragments” according to the present invention relate also to specific fragments of the sequences inserted into the vector pCR4-Topo and deposited as MERV-env, MERV-gag, MERV-prt and MERV-pol as mentioned above. Additionally, methods of using such sequences, polypeptides encoded by such sequences, antibodies directs against such sequences, and methods and compositions relating to the same are all contemplated.

Abstract: The invention discloses a use of dithiocarbamate compounds having the structural formula R1R2NCS2H, in which R1 and R2, independently of each other, represent a straight or branched C1-C4 alkyl, or, with the nitrogen atom, form an aliphatic ring with 4 to 6 C atoms, in which R1, R2, or the aliphatic ring is optionally substituted with one or more substituents selected from OH, NO2, NH2, COOH, SH, F, Cl, Br, I, methyl or ethyl, and oxidized forms of these compounds, in particular dimers thereof, as well as pharmaceutically acceptable salts thereof, to prepare an agent for treating or preventing an infection by RNA viruses which attack the respiratory tract and cause disease there.

Abstract: The invention relates to a method and a device for generating Alfvén waves, in which ionizable material is provided that penetrates a magnetic field. In order to create such a method or a device in which material can be conveyed based on the Alfvén waves, the magnetic field consists of a primary magnetic field that is periodically deformed by at least one oscillating secondary magnetic field that is polarized in the opposite direction from the primary field such that Alfvén waves are created in the ionizable material located in said magnetic field. The Alfvén waves propagate at a speed that depends on the density of the material penetrating the magnetic field and the field intensity of the magnetic field. The field intensity of the magnetic field is greater than the kinetic energy of the material located in the magnetic field such that material is conveyed by means of the Alfvén waves.

Abstract: The invention discloses a use of dithiocarbamate compounds having the structural formula R1R2NCS2H, in which R1 and R2, independently of each other, represent a straight or branched C1-C4 alkyl, or, with the nitrogen atom, form an aliphatic ring with 4 to 6 C atoms, in which R1, R2, or the aliphatic ring is optionally substituted with one or more substituents selected from OH, NO2, NH2, COOH, SH, F, Cl, Br, I, methyl or ethyl, and oxidized forms of these compounds, in particular dimers thereof, as well as pharmaceutically acceptable salts thereof, to prepare an agent for treating or preventing an infection by RNA viruses which attack the respiratory tract and cause disease there.

Abstract: Described is a polynucleotide molecule being a fragment of a polynucleotide sequence of an infectious human endogenous retrovirus, said polynucleotide molecule comprising a sequence selected from the group consisting of (a) a sequence with at least 98%, preferably 99%, still preferred 99.5%, identity to a sequence according to SEQ ID No 1, (b) a sequence which hybridises under stringent conditions with a nucleotide sequence according to said SEQ ID No 1, (c) a sequence which differs from said sequences (a) or (b) due to degeneration of the genetic code and (d) a sequence comprising sequences inserted into vectors pCR4-Topo and deposited as “MERV-env”, “MERV-gag”, “MERV-prt” and “MERV-pol” at the DSMZ on 26 Sep. 2001 or fragments thereof.